

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GenScript
BioTechCorp.**

Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026

AND

(2) AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES OF ASSOCIATION

Reference is made to (i) the announcement of Genscript Biotech Corporation (the “**Company**”) dated 10 April 2026 in respect of the Proposed Amendments to the Existing Memorandum and Articles and the adoption of the Amended Memorandum and Articles; (ii) the notice of the Annual General Meeting of the Company dated 13 April 2026 (the “**Notice of the Annual General Meeting**”); and (iii) the circular of the Company dated 13 April 2026 (the “**Circular**”) in respect of, among other things, the further details of the Proposed Amendments to the Existing Memorandum and Articles and the adoption of the Amended Memorandum and Articles. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026

The Board is pleased to announce that all the proposed resolutions set out in the Notice of the Annual General Meeting were duly passed by the Shareholders attending and voting at the Annual General Meeting held on 5 June 2026 by way of poll.

Directors’ Attendance

All the Directors were present at the Annual General Meeting either in person or by means of telecommunication.

Share Capital and Voting Entitlements

As at the date of the Annual General Meeting, (i) a total number of 2,188,417,343 Shares were in issue by the Company, which also represented the total number of Shares entitling the Shareholders to attend and vote at the Annual General Meeting (excluding Treasury Shares, if any); (ii) there was no repurchased Share pending cancellation that should be excluded from the total number of issued Shares entitling the Shareholders to attend and vote on all the resolutions at the Annual General Meeting; (iii) the Company did not hold any Treasury Shares (including any Treasury Shares held or deposited with the Central Clearing and Settlement System and no voting right of Treasury Shares has been exercised at the Annual General Meeting; and (iv) Computershare Hong Kong Trustees Limited (the Trustee of the 2019 RSU Scheme and the 2021 RSU Scheme) and the nominee account (of which the beneficial owners are the relevant grantees under the 2019 RSU Scheme and the 2021 RSU Scheme), which held 3,606,645 unvested Shares and 0 unvested Shares with voting rights attached respectively, representing approximately 0.16% and 0% of the total number of the issued Shares respectively, have abstained from voting on any of the resolutions at the Annual General Meeting.

The Directors, who are also the Shareholders, abstained from voting on the resolution numbered 2(E) in relation to the authorization of the Board to fix the remuneration of the Directors. Save as disclosed above, to the best knowledge, information and belief of the Company: (i) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules nor any Shareholders are required under the Listing Rules to abstain from voting at the Annual General Meeting; and (ii) no Shareholder has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the Annual General Meeting.

For the avoidance of doubt, holders of Treasury Shares (if any) must abstain from voting at the Annual General Meeting. Accordingly, save as disclosed above, the Shareholders holding an aggregate of 1,232,631,414 Shares (or their duly authorised proxies) were entitled to attend and vote on the resolutions proposed at the Annual General Meeting.

Scrutineer

The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the Annual General Meeting.

Poll Results

The poll results in respect of the resolutions proposed at the Annual General Meeting were as follows:

Ordinary Resolutions <i>(Note 1)</i>		No. of Votes (%) <i>(Note 2)</i>	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and auditor of the Company for the year ended 31 December 2025.	1,231,983,414 (99.947430%)	648,000 (0.052570%)
2.	(A) To re-elect Dr. Fangliang Zhang (“ Dr. Frank Zhang ”) as an executive Director.	1,230,391,406 (99.818274%)	2,240,008 (0.181726%)
	(B) To re-elect Mr. Jiange Meng (“ Mr. Robin Meng ”) as an executive Director.	1,187,312,381 (96.323391%)	45,319,033 (3.676609%)
	(C) To re-elect Dr. Li Zhu as an executive Director.	1,228,505,545 (99.665280%)	4,125,869 (0.334720%)
	(D) To re-elect Dr. Chenyang Shi (“ Dr. Victor Shi ”) as an independent non-executive Director.	1,227,289,944 (99.566661%)	5,341,470 (0.433339%)
	(E) To authorize the Board to fix remuneration of the Directors.	1,232,443,840 (99.984783%)	187,574 (0.015217%)
3.	To re-appoint Ernst & Young, Certified Public Accountants, as the auditor of the Company and to authorize the Board to fix remuneration of the auditor.	1,231,526,610 (99.910370%)	1,104,804 (0.089630%)
4.	(A) To give a general and unconditional mandate to the Directors to allot, issue and deal with new Shares (including any sale or transfer of the Treasury Shares, if any) not exceeding 20% of the number of the issued Shares (excluding the Treasury Shares, if any) as at the date of passing this resolution.	1,083,293,179 (87.884599%)	149,338,235 (12.115401%)
	(B) To give a general and unconditional mandate to the Directors to buy back Shares not exceeding 10% of the number of the issued Shares (excluding the Treasury Shares, if any) as at the date of passing this resolution.	1,232,564,979 (99.994610%)	66,435 (0.005390%)
	(C) To extend the authority given to the Directors pursuant to the ordinary resolution No. 4(A) to issue shares by adding the number of Shares bought back under the ordinary resolution No. 4(B).	1,086,979,748 (88.183681%)	145,651,666 (11.816319%)

Special Resolution <i>(Note 1)</i>		No. of Votes (%) <i>(Note 2)</i>	
		For	Against
5.	To approve the proposed amendments to the fourth amended and restated memorandum and articles of association of the Company currently in force and to adopt the fifth amended and restated memorandum and articles of association of the Company.	1,220,252,656 (98.995745%)	12,378,758 (1.004255%)

Notes:

1. The full text of the resolutions numbered 4 and 5 above are set out in the Notice of the Annual General Meeting.
2. All percentages have been rounded to six decimal places.

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 4 above, these resolutions were duly passed as ordinary resolutions of the Company. As more than 75% of the votes were cast in favour of the resolution numbered 5 above, that resolution was duly passed as a special resolution of the Company.

AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES OF ASSOCIATION

The Board announces that the resolution numbered 5 in relation to the Proposed Amendments to the Existing Memorandum and Articles and the adoption of the Amended Memorandum and Articles was duly passed as a special resolution of the Company by the Shareholders at the Annual General Meeting. The Amended Memorandum and Articles took effect on the date of the Annual General Meeting. The full text of the Amended Memorandum and Articles is available on the websites of the Stock Exchange and the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 5 June 2026

*As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.*